transdermal nicotine replacement therapy

Phase 3

transdermal nicotine replacement therapy is one of 10 therapeutic programs targeting Smoking. It is currently in Phase 3.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[2][1]

Indication

SmokingRecruiting

SmokingPhase 3

Recruiting

Competition

Competitive Landscape

10 competitors in Smoking

#DrugCompanyPhaseTrials

Nicorette

Pfizer

Approved

18 2

Wellbutrin

GGlaxo Dba Glaxosmithkline

Approved

5 3

Nicotine Free Cigarettes

Pfizer

Phase 3

5 4

Brenipatide

Eli Lilly

Phase 2

1 5

transdermal nicotine replacement therapy

DDuke University

Phase 3

1 6

Nicotine Replacement

GSK

Preclinical

1 7

Nicotine Gum

Johnson & Johnson

Preclinical

1 8

Nicorette

HHALEON

Preclinical

1 9

Nicotine Patches

UUniversity of California, San Diego

Preclinical

2 10

Nicoderm

OOttawa Heart Institute Research Corporation

Preclinical

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2030

ApprovedRecruiting

Smoking

NCT07089901

Clinical

Trials by Indication[1]

Smoking1 trial

Project DEDUCE: Digital Envirotyping to Develop Understanding of Cigarette Smoking and the Environment

Recruiting·DDuke University·Approved·NCT07089901·600 enrolled

Sources

References

[1]
ClinicalTrials.gov — 1 trial record for transdermal nicotine replacement therapy. U.S. National Library of Medicine, National Institutes of Health.
[2]
Open Targets Platform — Drug–disease associations for transdermal nicotine replacement therapy. EMBL-EBI & Wellcome Sanger Institute.
[3]
SEC EDGAR — Duke University company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Highest Phase: Phase 3[1]
Company: DDuke University

transdermal nicotine replacement therapy

Status by Indication[2][1]

Competitive Landscape

Expected Milestones

Q1 2030

Trials by Indication[1]

Smoking1 trial

References

Drug Info

Quick Facts

Related News